In addition, while hallmark oncogenes are expected to be disrupted in many cancer types, we observe in a sampling of 11 oncogenes that these are either not significantly differentially expressed in any of the 11 tumors analyzed (e.g., BCR, CTNNB1, DDX6, FUS, KRAS, MDM2, TPR) or only disrupted in certain tumors (e.g., EGFR, ETV4, JUN, MYC; Additional file 1: Fig. S1C). The gene discussed is KRAS; the disease is cancer.